首页> 外文OA文献 >Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

【2h】

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

机译：升级的Melphalan的最终结果280mg / m 2，具有氨毒素的细胞保护，遵循多种骨髓瘤的自体造血干细胞移植：高Cr和Vgpr率不会转化为改善的存活率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Parameswaran Hari; Donna E. Reece; Jasleen Randhawa; Neal Flomenberg; Dianna S. Howard; Ashrof Z. Badros; Aaron P. Rapoport; Barry R. Meisenberg; Joanne Filicko-Ohara; Gordon L. Phillips; David H. Vesole;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Final outcomes of escalated melphalan 280 mg/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival [J] . Hari Parameswaran, Reece Donna E., Randhawa Jasleen, Bone marrow transplantation . 2019,第2期

机译：升级的Melphalan的最终结果280 mg / m（2），具有氨化氨酸细胞保护，遵循多种骨髓瘤的自体造血干细胞移植：高CR和VGPR率不会转化为改善的存活率
2. Phase I study for poor-prognosis lymphoma: Augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation - a preliminary report. [J] . Phillips GL, Abboud CN, Bernstein SH, Seminars in Oncology . 2004,第6Suppla18期

机译：预后不良的淋巴瘤的第一阶段研究：使用氨磷汀细胞保护和自体造血干细胞移植，以逐渐增加剂量的美法仑增强“ BEAM”方案-初步报告。
3. A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function [J] . AbidiM.H., AgarwalR., TagejaN., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2013,第1期

机译：肾功能正常的多发性骨髓瘤患者的大剂量美法仑加Palifermin进行细胞保护及自体干细胞移植的I期剂量递增试验
4. TREATMENT OF AL AMYLOiDOSIS WITH TANDEM CYCLES OF HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION: FINAL ANALYSIS OF A PROSPECTIVE TRIAL [C] . V Sanchorawala, D.G.. Wright, K. Quillen, International Symposium on Amyloidosis . 2008

机译：高剂量梅酚和自体干细胞移植串联循环治疗Al淀粉样态的治疗方法：最终分析对前瞻性试验
5. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
6. Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial [O] . Muneer H. Abidi, Rishi Agarwal, Lois Ayash, -1

机译：Melphalan 180mg / m2可以安全地在多发性骨髓瘤患者中作为调理方案（ASCT）在多发性骨髓瘤患者中以肌酐清除60毫升/分钟/ 1.73m 2或低于使用帕尔米蛋白进行细胞保护剂：I阶段试验结果
7. Final Outcomes of Escalated Melphalan 280 mg/m2 Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (MM): High CR+VGPR Rate Does Not Translate Into Improved Survival [O] . Randhawa Jasleen K., Hari Parameswaran N., Reece Donna E., 2013

机译：在多发性骨髓瘤（MM）自体造血细胞移植之前，逐步升级的美法仑280 mg / m2的最终结果：高CR + VGPR率不能转化为生存率的提高

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

著录项

引文网络

相似文献

相关主题

期刊订阅